This information is intended for use by health professionals
Acidex Advance Oral Suspension (Peppermint Flavour)
Each 10 ml contains:
Potassium hydrogen carbonate
Ethyl parahydroxybenzoate (E214)
Propyl parahydroxybenzoate (E216)
15.0 mg/10 ml
5.50 mg/10 ml
2.50 mg/10 ml
For a full list of excipients, see section 6.1
Peppermint flavoured white or cream coloured suspension
Treatment of symptoms resulting from the reflux of acid, bile and pepsin into the oesophagus such as acid regurgitation, heartburn, indigestion (occurring due to the reflux of stomach contents), for instance, after gastric surgery, as a result of hiatus hernia, during pregnancy, accompanying reflux oesophagitis, including symptoms of laryngopharyngeal reflux such as hoarseness and other voice disorders, sore throats and cough. Can also be used to treat the symptoms of gastro-oesophageal reflux during concomitant treatment with or following withdrawal of acid suppressing therapy.
Adults and children 12 years and over: 5 -10ml after meals and at bedtime
Children under 12 years: Should be given only on medical advice.
Elderly: no dose modification is required in this age group.
This medicinal product is contraindicated in patients with known or suspected hypersensitivity to any of the ingredients, or any of the excipients listed in section 6.1, including the esters of hydroxybenzoates (Parabens) (see section 4.4).
If symptoms do not improve after seven days, the clinical situation should be reviewed.
This medicinal product contains about 106 mg (5.1mmol) sodium per 10 ml dose, equivalent to 5.3% of the WHO recommended maximum daily intake for sodium.
The maximum daily dose of this product is equivalent to 21% of the WHO recommended maximum daily intake for sodium.
This product is considered high in sodium. This should particularly be taken into account for those on a low salt diet (e.g in some cases of congestive cardiac failure and renal impairment).
Potassium: This medicine contains 78 mg (2.0 mmol) potassium per 10 ml dose. To be taken into consideration by patients with reduced kidney function or patients on a controlled potassium diet.
Each 10ml contains 200 mg (2.0 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.
Contains parahydroxybenzoates (E214, E216); may cause allergic reactions (possibly delayed)
A time-interval of 2 hours should be considered between Acidex Advance intake and the administration of other medicinal products, especially tetracyclines, fluoroquinolones, iron salts, thyroid hormones, chloroquine, bisphosphonates, and estramustine.
Clinical studies in more than 500 pregnant women as well as a large amount of data from post-marketing experience indicate no malformative nor foeto/neonatal toxicity of the active substances. Acidex Advance can be used during pregnancy, if clinically needed.
No known effect on breast fed infants. Acidex Advance can be used during breast feeding.
No known effect on human fertility.
Adverse reactions have been ranked under headings of frequency using the following convention: very common (>1/10), common (>1/100 and <1/10), uncommon (>1/1000 and < 1/100), rare (>1/10,000 and <1, 1000), very rare (<1/10,000 cases), and not known (cannot be estimated from the available data).
System Organ Class
Immune System Disorders
Anaphylactic and anaphylactoid reactions. Hypersensitivity reactions such as urticaria.
Respiratory, Thoracic and Mediastinal Disorders
Respiratory effects such as bronchospasm.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms are likely to be minor; some abdominal discomfort may be experienced.
In the event of overdose, symptomatic treatment should be given.
ATC Code: A02BX13
Pharmaceutical group: Other drugs for peptic ulcer and gastro-oesophageal reflux
On ingestion the suspension reacts with gastric acid to rapidly form a raft of alginic acid gel having a near-neutral pH which floats on the stomach contents quickly and effectively impeding gastro-oesophageal reflux for up to 4 hours, and protecting the oesophagus from acid, pepsin and bile. In severe cases the raft itself may be refluxed into the oesophagus in preference to the stomach contents and exert a demulcent effect. In addition in vitro evidence has shown that the raft has a secondary action and is able to entrap bile and pepsin within its structure, further protecting the oesophagus from these gastric components.
The mode of action of the product is physical and does not depend on absorption into the systemic circulation.
There are no preclinical data of relevance to the prescriber in addition to that included in other sections of the SmPC.
Ethyl Parahydroxybenzoate (E214)
Propyl Parahydroxybenzoate (E216)
Use within 3 months of opening
Do not store above 25°C. Do not refrigerate or freeze.
Pharmaceutical Grade Type III amber glass bottles with white polypropylene caps that have a Low density Polyethylene (LDPE) liner
Pack sizes: 150ml, 200ml, 250ml and 500ml.
Not all pack sizes may be marketed.
Wockhardt UK Ltd
Ash Road North